THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History* Fertility-Sparing Treatment (for Gynecologic Malignancies and Pre-malignancies)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

INITIAL PRESENTATION

EVALUATION

DISPOSITION



¹ Endometrial hyperplasia, early endometrial cancer, early cervical cancer, early ovarian cancer, borderline tumors, etc.

² Hormonal contraception, chronic corticosteroid use

THE UNIVERSITY OF TEXAS

Making Cancer History®

MDAnderson Cancer Center Making Cancer Histors^{*} (for Gynecologic Malignancies and Pre-malignancies)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

APPENDIX A: Fertility Consults and Referrals

Oncofertility Program at MD Anderson

Established in 2012, the MD Anderson Oncofertility Service offers comprehensive fertility counseling and services to MD Anderson patients before and after treatment. Housed in the Department of Gynecologic Oncology and Reproductive Medicine, it is staffed by two board-certified Reproductive Endocrinology and Infertility specialists and an Advanced Practice Provider with expertise in oncofertility. The service offers:

- Comprehensive, patient-centered fertility counseling before and after cancer treatment
- Assessment of fertility status
- Discussion of options for parenthood after cancer
- Streamlined access to fertility preservation methods including ovarian and testicular tissue freezing, egg freezing, sperm banking, and embryo freezing through our partnership with Baylor College of Medicine
- Streamlined access to post-treatment fertility options including ovulation induction, intrauterine insemination, in vitro fertilization (IVF) and third-party reproduction (donor eggs, donor sperm, donor embryos, and gestational carriers)
- Discussion of preimplantation genetic testing, including PGT-A and PGT-M for patients who carry inherited mutations that can cause cancer
- Ovarian suppression with medicines such as GnRH analogs
- Collaborative care with the oncologist

To order consult or referral

- Ambulatory referral: Place order for Ambulatory Referral to Gynecologic Oncology and choose Oncofertility button.
- Inpatient consult: Place order for Consult to Fertility Specialist and e-mail: fertility@mdanderson.org
- For any urgent consults and referrals: e-mail: fertility@mdanderson.org

Adolescents and Young Adults (AYA) at MD Anderson

The MD Anderson AYA program serves patients whether in active treatment or posttherapy survivorship. The AYA team includes both pediatric and adult oncologists, two Advanced Practice Providers with expertise in survivorship and late effects, a psychologist with training in vocational counseling, and a dedicated social work counselor. Through our comprehensive services, the program can help AYAs with coping, relationships, school, career goals, long-term health, quality of life issues, and fertility concerns. In regard to fertility, the service offers:

- Fertility risk counseling
- Education regarding fertility preservation options
- Assistance identifying financial and support resources

To order consult or referral

- Ambulatory referral: place order for Ambulatory referral to AYA and select Fertility counseling as reason for referral
- Inpatient consult:
- Page Janae Harris, BSN, RN, CPHON at 713-606-1423
- E-mail: aya@mdanderson.org

• For general questions:

- Call the Child and Adolescent Center Clinic at 713-792-6610
- E-mail: aya@mdanderson.org

Making Cancer History®

MDAnderson Cancer Center (for Currently June 1997) (for Gynecologic Malignancies and Pre-malignancies)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

APPENDIX B: Patient Education and Websites

MDACC Patient Education (available through Patient Education Online)

- Fertility Preservation Options for Men and Women
- Fertility Options for Women Diagnosed with Cancer
- Emotional and Psychological Aspects of Fertility Preservation
- Oocyte Cryopreservation
- Ovarian Reserve Testing
- Fertility and Cancer Recommended Resources (The Learning Center): Provides a list of pamphlets, books and websites that are available to patients

Websites

www.ReproductiveFacts.org: The patient education website of the American Society for Reproductive Medicine. Under the publications tab, it includes printable informational booklets and fact sheets about a variety of issues including "Age and Fertility," "Assisted Reproductive Technologies," "Cancer and Fertility Preservation," "Adoption," and "Third Party Reproduction."

www.livestrong.org: The national LIVESTRONG initiative dedicated to providing reproductive information, support and hope to cancer patients and survivors whose medical treatments present the risk of infertility. In addition to providing patient education and support, it also offers financial assistance for fertility and family building services.

THE UNIVERSITY OF TEXAS MDAnderson Fertility-Sparing Treatment Cancer Center (for Gynecologic Malignancies and Pre-malignancies)

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

SUGGESTED READINGS

- American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. (2013). Mature oocyte cryopreservation: A guideline. Fertility and Sterility, 99(1), 37-43. doi:10.1016/j.fertnstert.2012.09.028
- Anderson, R. A., & Wallace, W. H. B. (2013). Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertility and Sterility, 99(6), 1469-1475. doi:10.1016/j.fertnstert.2013.03.014
- Bedoschi, G., & Oktay, K. (2013). Current approach to fertility preservation by embryo cryopreservation. Fertility and Sterility, 99(6), 1496-1502. doi:10.1016/j.fertnstert.2013.03.020
- Cakmak, H., & Rosen, M. P. (2013). Ovarian stimulation in cancer patients. Fertility and Sterility, 99(6), 1476-1484. doi:10.1016/j.fertnstert.2013.03.029
- Chan, J. L. & Wang, E. T. (2017). Oncofertility for women with gynecologic malignancies. Gynecologic Oncology 144(3), 631-636. doi:10.1016/j.ygyno.2016.12.013
- Chen, L. M., Blank, S. V., Burton, E., Glass, K., Penick, E., & Woodard, T. (2019). Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine evidence-based review. Gynecologic Oncology, 155(3), 508-514. doi:10.1016/j.ygyno.2019.06.017
- Chitoran, E., Rotaru, V., Mitroiu, M. N., Durdu, C. E., Bohiltea, R. E., Ionescu, S. O., ... Simion, L. (2024). Navigating fertility preservation options in gynecological cancers: A comprehensive review. Cancers. 16(12), 2214. doi:10.3390/cancers16122214
- Cobo, A., Garcia-Velasco, J. A., Domingo, J., Remohí, J., & Pellicer, A. (2013). Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients?. Fertility and Sterility, 99(6), 1485-1495. doi:10.1016/j.fertnstert.2013.02.050
- Donnez, J. (2013). Introduction: Fertility preservation, from cancer to benign disease to social reasons: the challenge of the present decade. Fertility and Sterility, 99(6):1467-8. doi:10.1016/ j.fertnstert.2013.03.040
- Eskander, R. N., Randall, L. M., Berman, M. L., Tewari, K. S., Disaia, P. J., & Bristow, R. E. (2011). Fertility preserving options in patients with gynecologic malignancies. American Journal of Obstetrics and Gynecology, 205(2), 103-110. doi:10.1016/j.ajog.2011.01.025
- Floyd J. L., Campbell S., Rauh-Hain J. A., & Woodard T. (2020). Fertility preservation in women with early-stage gynecologic cancer: Optimizing oncologic and reproductive outcomes. International Journal of Gynecological Cancer, 31(3), 345-351. doi:10.1136/ijgc-2020-001328.
- Georgescu, E. S., Goldberg, J. M., du Plessis, S. S., & Agarwal, A. (2008). Present and future fertility preservation strategies for female cancer patients. Obstetrical & Gynecological Survey, 63(11), 725-732, doi:10.1097/OGX.0b013e318186aaea
- Gonçalves, V., Ferreira, P. L., Saleh, M., Tamargo, C., & Quinn, G. P. (2022). Perspectives of young women with gynecologic cancers on fertility and fertility preservation: A systematic review. The Oncologist, 27(3), e251-e264. doi:10.1093/oncolo/oyab051

Continued on next page

THE UNIVERSITY OF TEXAS MDAnderson Fertility-Sparing Treatment Cancer Center (for Gynecologic Malignancies and Pre-malignancies)

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

SUGGESTED READINGS - continued

- Holman, D. A. (2019). Fertility preservation in gynecologic cancer. Seminars in Oncology Nursing, 35(2), 202-210. doi:10.1016/j.soncn.2019.02.007
- Kidger, J., Murdoch, J., Donovan, J. L., & Blazeby, J. M. (2009). Clinical decision-making in a multidisciplinary gynaecological cancer team: A qualitative study. BJOG: An International Journal of Obstetrics & Gynecology, 116(4), 511-517. doi:10.1111/j.1471-0528.2008.02066.x
- Marhhom, E., & Cohen, I. (2007). Fertility preservation options for women with malignancies. Obstetrical & Gynecological Survey, 62(1), 58-72. doi:10.1097/01.ogx.0000251029.93792.5d
- National Comprehensive Cancer Network. (2024) Clinical Practice Guidelines for Adolescent and Young Adult (AYA) Oncology. (Version 1.2025). Retrieved from https:// www.nccn.org/professionals/physician gls/pdf/aya.pdf
- Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., ... Loren, A. W. (2018). Fertility preservation in patients with cancer: ASCO clinical practice guideline update. Journal of Clinical Oncology, 36(19):1994-2001. doi:10.1200/JCO.2018.78.1914
- Sainio, C., Eriksson, E., & Lauri, S. (2001). Patient participation in decision making about care: The cancer patient's point of view. Cancer Nursing, 24(3), 172-179. Retrieved from https:// journals.lww.com/cancernursingonline/fulltext/2001/06000/Patient Participation in Decision Making About.00002.aspx
- Stewart, K., Campbell, S., Frumovitz, M., Ramirez, P. T., & McKenzie, L. J. (2021). Fertility considerations prior to conservative management of gynecologic cancers. International Journal of Gynecologic Cancer, 31(3). doi:10.1136/ijgc-2020-001783
- Taylan, E., & Oktay, K. (2019). Fertility preservation in gynecologic cancers. Gynecologic Oncology, 155(3), 522-529. doi:10.1016/j.ygyno.2019.09.012
- Tomao, F., Peccatori, F., Del Pup, L., Franchi, D., Zanagnolo, V., Panici, P. B., & Colombo, N. (2016). Special issues in fertility preservation for gynecologic malignancies. Critical Reviews in Oncology/Hematology, 97, 206-219. doi:10.1016/j.critrevonc.2015.08.024
- West, E. R., Zelinski, M. B., Kondapalli, L. A., Gracia, C., Chang, J., Coutifaris, C., ... Woodruff, T. K. (2009). Preserving female fertility following cancer treatment: Current options and future possibilities. Pediatric Blood & Cancer, 53(2), 289-295. doi:10.1002/pbc.21999

Making Cancer History®

MDAnderson Cancer Center (for Currently June 1997) (for Gynecologic Malignancies and Pre-malignancies)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

DEVELOPMENT CREDITS

This practice consensus statement is based on majority expert opinion of the Fertility-Sparing Treatment for Gynecologic Malignancies and Pre-malignancies workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Core Development Team Leads

Terri Lynn Woodard, MD (Gynecologic Oncology & Reproductive Medicine)

Workgroup Members

Olga N. Fleckenstein, BS[•] Brittnee Macintyre, MSN, APRN, FNP-C[•] Laurie McKenzie, MD (Gynecologic Oncology & Reproductive Medicine) Jose Alejandro Rauh-Hain, MD (Gynecologic Oncology & Reproductive Medicine) Pamela Soliman, MD (Gynecologic Oncology & Reproductive Medicine) Payton L. Ten Hagen, DNP, APRN, FNP-C, AOCNP (Gynecologic Oncology & Reproductive Medicine) Roni Wilke, MD (Gynecologic Oncology & Reproductive Medicine)

* Clinical Effectiveness Development Team